本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 投资标的名称：北京中科鸿泰医疗科技有限公司（以下简称"中科鸿泰"、"标的公司"） ● 投资金额：江西金达莱环保股份有限公司（以下简称"公司"、"金达莱"）拟使用自有资金3000万元向 中科鸿泰增资，交易完成后公司将持有中科鸿泰10.00%的股权 ● 已履行的审议程序：本次对外投资事项已经公司内部审议程序批准，无需提交董事会、股东会审议通 过。本次对外投资不构成《上市公司重大资产重组管理办法》规定的重大资产重组，亦不构成关联交 易。 ● 相关风险提示：标的公司目前尚未盈利，实际经营过程中可能受行业政策、市场准入、市场推广、运 营管理等因素的影响，未来具体经营业绩及投资收益仍存在不确定性。敬请广大投资者谨慎决策，注意 投资风险。 一、对外投资概述 （一）本次交易概况 1、本次交易概况 公司基于对医疗机器人技术与系统的研发及应用等国家战略性新兴行业发展前景看好，拟逐步优化公司 产业结构，为未来发展寻找新的产业机会，以提高公司的抗风险能力，培育新的利润增长点。公司拟以 ...

Core Viewpoint - Company plans to invest 30 million yuan in Zhongke Hongtai to acquire a 10% stake, aiming to optimize its industrial structure and explore new growth opportunities in the medical robotics sector [2] Group 1: Investment Details - The investment is based on the positive outlook for the development of medical robotics technology and applications in strategic emerging industries [2] - The investment will enhance the company's risk resistance and cultivate new profit growth points [2] Group 2: Zhongke Hongtai Overview - Zhongke Hongtai specializes in the research, production, and sales of medical robotics technology and systems, being a technology transfer enterprise incubated by the Chinese Academy of Sciences [2] - The founding team has undertaken over 10 major projects, including the first domestic "863 Program" for vascular interventional surgical robots since 2008, establishing itself as a pioneer in the field [2] - The company holds over 100 independent intellectual property rights and has participated in the formulation of 2 industry standards [2] Group 3: Product Advantages - Zhongke Hongtai's multi-channel vascular interventional surgical robot features bionic design, allowing simultaneous rotation and pushing of guidewires, and can operate two guidewires and two balloon/stent catheters simultaneously [3] - The robot includes force feedback functionality and can perform remote surgeries, full-process robotic assistance, and data collection [3] Group 4: Clinical Trials and Future Plans - The product requires clinical trials before market registration, with the first patient enrolled in a clinical trial for the world's first multi-channel fully assisted vascular interventional surgical robot on November 25, 2025 [3] - As of the announcement date, 16 clinical trials have been completed, and the company is accelerating progress [3] Group 5: Company Strategy - The company is an advanced innovative comprehensive service provider for water environment governance and plans to invest in non-listed companies in the health sector, including medical devices and biomanufacturing, to optimize its industrial structure [2][3]

本次活动围绕微纳机器人与精密操控、具身智能与人机共融、工业机器人与智能制造、机器人学习与智能控制、医疗机器人、仿生与软体机 器人六个专题展开深入研讨。来自清华大学、北京大学、香港大学、浙江大学等多所知名高校、科研机构的专家学者、博士后研究人员、博士生 200余人参会。本次活动还特设"青年人才发展政策宣讲会"，系统解读人才支持政策，邀请优秀留校博士后分享经验。 图为交流活动现场。（受访单位供图） 新华网沈阳12月16日电（记者白涌泉）12月12日至15日，由全国博士后管委会办公室、人力资源和社会保障部留学人员和专家服务中心（中 国博士后科学基金会）指导，辽宁省人力资源和社会保障厅主办，大连理工大学承办的"机器人与智能系统前沿领域"全国博士后学术交流活动在 大连成功举办。 全国博士后管委会办公室、人力资源和社会保障部留学人员和专家服务中心持续实施国家博士后学术交流计划，每年支持开展系列高水平学 术活动，搭建前沿交流平台。本次交流活动聚焦"机器人与智能系统前沿领域"，旨在构建高层次学术合作平台，推动该领域的原始创新与产学研 融合。 ...

雷军旗下顺为资本从A轮开始，连续领投/跟投了3次，为最大机构股东。 雷军又要收获IPO了。 近日，北京术锐机器人股份有限公司（下称"术锐机器人"）在北京证监局完成IPO导备案登记，辅导机构仍为2023年首次签约的中信证券。 至此，这家由雷军旗下顺为资本连续3轮领投/参投的单孔腔镜手术机器人公司，正式拉开第二次A股冲刺大幕。 第二次冲刺IPO 创始人控制54.58%表决权 2023年3月，术锐与中信证券首次签署辅导协议，同年完成辅导验收，但并未立刻递交招股说明书。 2025年11月，双方再次签订辅导协议；12月2日，北京证监局官网挂出最新辅导备案报告，标志二次辅导正式启动。 IPO前，公司创始人、上海交通大学教授徐凯直接持股22.74%，并通过三家员工持股平台（北京术成、海南术睿、上海术瑞）间接控制31.84%表决权，合 计54.58%握有绝对话语权。 其余股份则由顺为、美敦力、国投招商、天峰资本、正心谷等10余家知名机构持有。 值得一提的是，在备案信息中，术锐未限定科创板或创业板。但据个别媒体援引投行人士放出的消息称，"以术锐的'硬科技'属性，冲刺科创板概率更 高。" 教授带队创业 据官网资料，北京术锐机器人 ...

Summary of PROCEPT BioRobotics FY Conference Call (December 02, 2025) Company Overview - **Company**: PROCEPT BioRobotics (NasdaqGM:PRCT) - **Industry**: Medical Technology, specifically in urology and robotic-assisted procedures Key Points and Arguments Utilization and Inventory Management - The CEO clarified that the decline in HP sales does not indicate a problem with procedure volumes but rather an inventory workdown issue [3][4] - The company is focusing on procedure volume rather than just stocking orders, which are seen as noise in the system [3][4] - Adjustments were made to guidance based on the analysis that many sites were carrying excess inventory [4] Procedure Growth - The company is pleased with the adoption of its therapy and is focusing on procedural growth [5] - The CEO emphasized the importance of efficient launches and training for new centers to drive better utilization [12][13] - A pilot program was initiated to improve the launch process, which has shown benefits [12] Patient Engagement and Market Penetration - The CEO discussed the need to educate patients about the benefits of their procedures, particularly in terms of safety and outcomes [37][38] - There is a significant opportunity to convert patients who are currently hesitant to undergo procedures due to fears of complications [25][28] Competitive Landscape - The company believes it occupies a unique position in the market, offering effective procedures with a low complication profile compared to other options [42] - The CEO highlighted the need to change the narrative around non-receptive procedures, which may initially seem attractive but lack durability [46] Capital Sales and Replacement Cycle - The capital sales team performed well despite increased scrutiny in the capital process, with a strong outlook for future placements [52][54] - The company is developing a cohesive replacement strategy for its AquaBeam systems, which is expected to become significant in 2026 [58][61] Financial Guidance - The CEO expressed confidence in the guidance provided, which reflects a status quo but also acknowledges opportunities for improvement [66][68] - Better commercial execution and the ability to replace legacy systems are seen as key drivers for achieving the high end of guidance [68] Reimbursement Landscape - Facility payments to hospitals have increased by 5% year-over-year, making the economic case for the company's procedures favorable [70] - The CEO noted that the adoption of aquablation therapy is driven more by clinical outcomes than by economic factors [71] Marketing and Education - The company plans to utilize social media and referral community education rather than large-scale advertising to promote its procedures [77] Additional Important Insights - The management team is focused on improving the training and specialization of their field staff to enhance overall performance [22][23] - The CEO's experience from previous roles is being leveraged to improve operational efficiency and patient outcomes at PROCEPT [24][25] This summary captures the essential points discussed during the conference call, highlighting the company's strategic focus on procedure growth, patient education, and operational efficiency in the medical technology sector.

Core Insights - The article highlights the establishment of the Fuzhou Innovation Center, which focuses on developing medical robots and aims to create a robust ecosystem for smart medical equipment [5][11] - The center has made significant advancements in medical robot research and development, including the creation of a humanoid robot training ground that will assist healthcare professionals in various medical services [6][10] Group 1: Technological Advancements - The Fuzhou Innovation Center has developed a high-fidelity, multi-task immersive training environment for humanoid robots, achieving significant progress in data accumulation and algorithm iteration [6] - The center has created over 200 customized training modes for Alzheimer's disease prevention and rehabilitation, and has developed a robotic platform for automated medical experiments [6][9] - The center's collaboration with Newton Technology aims to provide comprehensive support for robot certification, enhancing the safety and reliability of robots in medical applications [7][9] Group 2: Ecosystem Development - The Fuzhou Innovation Center is focused on building a collaborative network within the medical robot industry, facilitating connections between startups and established enterprises [10][12] - The center has hosted events to showcase innovative projects in the robotics field, providing a platform for capital connection and policy promotion [10] - The center's strategic location in Fuzhou New Area, which is recognized for its supportive policies and industrial resources, enhances its potential for growth and innovation [11][12] Group 3: Future Prospects - The Fuzhou Innovation Center aims to achieve significant technology transfer and economic scale within the next 3 to 5 years, positioning itself as a key player in the medical robot sector [12] - The center's commitment to fostering talent and integrating various sectors will contribute to the sustainable development of the medical robot industry in the region [12]

Core Viewpoint - The company provides optoelectronic liquid interconnection solutions for the new generation of information technology and data center fields [1] Group 1: Brain-Computer Interface - The company offers lightweight and quick ICP series plastic plug-and-play connectors and components for connecting collected brainwave signals to peripheral devices [1] Group 2: Medical Robotics - The company provides integrated mixed transmission of network signals, control signals, and power signals through the MG series connectors and components, facilitating stable and efficient operation of medical robots [1]

Core Insights - Minhang District has achieved significant economic milestones, with a GDP surpassing 400 billion yuan and total fiscal revenue exceeding 90 billion yuan, ranking second in Shanghai [1] - The district's leadership emphasizes its strategic location as a vital hub connecting the Yangtze River Delta and the global market [1] Economic Development - Minhang has maintained a research and development expenditure of approximately 8% of its GDP, leading the city in this regard, reflecting a long-term commitment to investment in innovation [3] - The district has received 13 national science and technology awards and 210 municipal awards during the 14th Five-Year Plan period, showcasing its focus on fostering specialized and innovative enterprises [3] - The establishment of the "Haijuyingcai" entrepreneurship park aims to support talent and innovation through various zero-cost and zero-burden initiatives [3] Industrial Growth - Minhang is actively developing three major industrial clusters: advanced energy equipment and green low-carbon, aerospace, and biomedicine [3] - The "Brain-Intelligence World" industrial park, dedicated to brain-computer interface technology, is under construction, covering an area of 100,000 square meters and attracting 10 companies in the sector [3][4] Strategic Initiatives - The "Greater Hongqiao" initiative has positioned Minhang as a key player in internationalization and dual circulation, with significant growth in the Hongqiao International Central Business District [5][6] - The district has seen the establishment of 28,000 enterprises, including 275 headquarters, with tax revenues exceeding 10 billion yuan for two consecutive years [5] Innovation and Collaboration - Minhang aims to create a world-class innovation bay area, with the establishment of a 10 billion yuan "Dalinghao Bay Technology Innovation Fund" to support technological advancements [7] - Collaboration with local universities has led to the establishment of nearly 200 companies focused on compliance entrepreneurship, enhancing the region's innovation ecosystem [7] Future Vision - Minhang's future goals include becoming an international open hub, a source of technological innovation, a highland for new industrial chains, and a model for urban living [7]

Group 1 - The core viewpoint of the article is that Weifeng Electronics (301328.SZ) has made progress in the medical robotics field, with some products already in application, such as connectors for surgical robot control systems, which have achieved small-scale supply [1] - The company is focusing on the industrialization process and the pace of scaling up, which will depend on the development cycle of downstream customers [1] - Weifeng Electronics will continue to monitor industry demand and deepen its layout in niche areas [1]

Core Insights - A new soft robotic intubation system (SRIS) developed by research teams from Stanford University and UC Santa Barbara shows significant improvements in intubation success rates and time efficiency compared to traditional methods [3][6][17] - The system allows for autonomous navigation into the trachea, requiring minimal training for users, which could revolutionize emergency medical procedures, especially in resource-limited settings [3][17][18] Group 1: Traditional Intubation Challenges - Intubation is a critical procedure for airway protection, but it faces high failure rates, with pre-hospital settings showing up to 35% failure and emergency departments at 15-20% [6] - Environmental factors such as blood and vomit in the airway, poor lighting, and patient positioning contribute to these challenges, along with the skill level of emergency personnel [6] - The consequences of failed intubation attempts can be severe, leading to hypoxia and cardiac arrest, which directly threaten patient lives [6] Group 2: Soft Robotic Intubation System Features - The soft robotic system mimics biological growth mechanisms, allowing for a "tip extension" approach that enhances navigation through the airway [8][11] - The system consists of a guide and a self-guided tube, which together provide significant advantages in terms of force application and tolerance to misalignment [11][12] - In mechanical tests, the soft robot applied an average axial force of only 1.5 Newtons, compared to 10.3 Newtons for traditional devices, showcasing its gentler approach [11] Group 3: Performance in Testing - Expert users achieved a 100% success rate with the soft robotic system in human models, with an average intubation time of just 7.4 seconds [12] - Non-expert users, after only 5 minutes of training, achieved an 87% first-attempt success rate and a 96% overall success rate with the soft robot, significantly outperforming traditional video laryngoscopy [15] - In challenging cases, the soft robot's first-attempt success rate reached 93%, compared to just 36% for traditional methods [17][20] Group 4: Implications for Emergency Medicine - The soft robotic intubation system has the potential to improve success rates and reduce complications in emergency intubations, particularly in pre-hospital and disaster medical scenarios [17][18] - In developed countries, it could enhance emergency care, while in developing regions, it may democratize access to essential airway management [17][18] - The technology is still in preclinical stages, with plans for larger clinical trials and regulatory approval from the FDA [18]